Aduro Biotech, Inc. (NASDAQ:ADRO) Broker Price Targets For The Coming Week
Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Aduro Biotech, Inc. (NASDAQ:ADRO).
Recent broker ratings and price targets:
11/21/2016 – Aduro Biotech, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 20 price target on the stock.
11/14/2016 – Aduro Biotech, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 20 price target on the stock.
10/24/2016 – Aduro Biotech, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 14 price target on the stock.
03/15/2016 – Aduro Biotech, Inc. was downgraded to “underperform” by analysts at Bank of America Merrill Lynch. They now have a USD 14 price target on the stock.
12/16/2015 – Aduro Biotech, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity.
12/01/2015 – Aduro Biotech, Inc. was downgraded to “perform” by analysts at Oppenheimer. They now have a USD 30 price target on the stock.
11/24/2015 – Aduro Biotech, Inc. had its “outperform” rating reiterated by analysts at William Blair.
Aduro Biotech, Inc. has a 50 day moving average of 12.33 and a 200 day moving average of 13.01. The stock’s market capitalization is 749.08M, it has a 52-week low of 7.26 and a 52-week high of 30.20.
The share price of the company (NASDAQ:ADRO) was down -0.45%, with a high of 11.57 during the day and the volume of Aduro Biotech, Inc. shares traded was 425438.
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway kmspico 10.0.4 activator free download  platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
Receive Aduro Biotech, Inc. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech, Inc. with MarketBeat.com's FREE daily email newsletter.
via source:http://www.fiscalstandard.com/2016/12/17/aduro-biotech-inc-nasdaqadro-broker-price-targets-for-the-coming-week-6/


















